Related Experiment Video
Updated: Mar 21, 2026

10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
8.1K
Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy
Joanna A Krupka1, Alimu Dayimu1, Daniel J Hodson1
1Joanna A. Krupka, MB PhD, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom, Department of Haematology, University of Cambridge, Cambridge, United Kingdom; Alimu Dayimu, PhD, Cambridge Clinical Trials Unit-Cancer Theme, University of Cambridge, Cambridge, United Kingdom; and Daniel J. Hodson, MB PhD, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom, Department of Haematology, University of Cambridge, Cambridge, United Kingdom.
Summary
No abstract available in PubMed .

